AFIB News and Press, Acutus Medical Inc. From 11/12/21

Image source: The Motley Fool. Acutus Medical, Inc. (NASDAQ: AFIB) Q3 2021 Earnings Call Nov 11, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Acutus Medical, Inc. (AFIB) Q3 2021 Earnings Call Transcript

Acutus Medical, Inc. (AFIB) Q3 2021 Earnings Conference Call November 11, 2021 4:30 PM ET Company Participants Caroline Corner – Investor Relations Vince Burgess – President and Chief Executive Officer David Roman – Chief Financial Officer Conference Call Participants Rob...

Acutus Medical (NASDAQ:AFIB) announces the initiation of a CE mark study for focal pulsed field ablation therapy to treat atrial fibrillation (AF). AcQForce PFA-CE is a prospective, non-randomized European clinical study designed to demonstrate the safety and performance of the Acutus Pu...

Acutus Medical (NASDAQ:AFIB): Q3 GAAP EPS of -$0.94 misses by $0.07. Revenue of $4.6M (+45.1% Y/Y) misses by $1.08M. Press Release For further details see: Acutus Medical EPS misses by $0.07, misses on revenue

CARLSBAD, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (Nasdaq: AFIB) (“Acutus”), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the initiation of AcQForce PFA-CE, a new clinica...

CARLSBAD, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the third ...

Research Highlights : Adults who had atrial fibrillation (AFib) and type 1 or type 2 diabetes were less likely to notice heartbeat irregularities compared to people who had AFib without either type 1 or type 2 diabetes. People who have either type 1 or type 2 diabetes and AFib tended to...

CARLSBAD, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today it will release its financial results for the third ...

( NewMediaWire ) - October 26, 2021 - DALLAS - Until now, scientific research about treatment for the most common type of heart arrythmia, atrial fibrillation (AFib ), has primarily focused on patients with already established cases of the condition. CHANGE AFib , a new pragmatic clinical ...

Acutus Medical, Inc.’s superior contactless mapping technology threatens to change and expand the ablation treatment paradigm for cardiac arrhythmias. However, the company’s launch has been disappointing with the pandemic being held out as the scapegoat. With a new c...